CHOP方案联合美罗华治疗初治弥漫性大B细胞淋巴瘤的效果分析  

Analysis on the effect of CHOP combined with rituximab in the treatment of newly treated diffuse large B-cell lymphoma

作　　者：王引舟[1] WANG Yinzhou(Department of Hematology,the Second Hospital of Sanming City in Fujian Province,Sanming 366000,China)

机构地区：[1]福建省三明市第二医院血液科,福建三明366000

出　　处：《中国现代医生》2018年第16期103-105,共3页China Modern Doctor

摘　　要：目的探讨CHOP方案联合美罗华治疗初治弥漫性大B细胞淋巴瘤的应用效果。方法选择2016年6月~2017年7月90例初治弥漫性大B细胞淋巴瘤患者。以随机数字表法分组,对照组给予单一CHOP方案治疗,观察组则给予CHOP方案联合美罗华治疗。比较两组初治弥漫性大B细胞淋巴瘤控制率、无进展生存时间、总生存时间、干预前后患者卡氏(KPS)评分、生活质量(QOL)评分、药物不良反应率。结果观察组初治弥漫性大B细胞淋巴瘤控制率高于对照组(P<0.05);观察组无进展生存时间、总生存时间长于对照组(P<0.05);干预前两组KPS评分、QOL评分相近(P>0.05);干预后观察组KPS评分、QOL评分优于对照组(P<0.05)。观察组药物不良反应率和对照组无明显差异(P>0.05)。其中,观察组出现发热、骨髓抑制等不良反应,与对照组的发生率相似。结论 CHOP方案联合美罗华治疗初治弥漫性大B细胞淋巴瘤的应用效果确切,可有效改善改善症状,延长生存时间,提高健康水平和改善生活质量,且无严重不良反应,安全有效,值得推广应用。Objective To investigate the application effect of CHOP regimen combined with rituximab in the treatment of newly treated diffuse large B-cell lymphoma.Methods A total of 90 patients with newly treated diffuse large B-cell lymphoma from June 2016 to July 2017 were selected,and assigned to groups according to a random number table method.The control group was given a single CHOP regimen.The observation group was given CHOP regimen combined with rituximab for treatment.The control rates of newly treated diffuse large B-cell lymphoma,progression-free survival time,total survival time,KPS score,quality of life(QOL)score before and after intervention,adverse drug reaction rate were compared between the two groups.Results The control rate of newly treated diffuse large B-cell lymphoma in the observation group was higher than that in the control group(P<0.05);the progression-free survival time and overall survival time in the observation group were longer than those in the control group(P<0.05);the KPS score and QOL score were similar between the two groups before intervention(P>0.05);after the intervention,the KPS score and QOL score in the observation group were better than those in the control group(P<0.05).The rate of adverse drug reactions in the observation group was not significantly different from that in the control group(P>0.05).Among them,the observation group had fever,bone marrow suppression and other adverse reactions,which were similar to the incidence rate in the control group.Conclusion CHOP regimen combined with rituximab in the patients with newly treated diffuse large B-cell lymphoma has an exact application effect,which can effectively improve the symptoms,prolong the survival time,improve the health condition and improve the quality of life,without serious side effects.It is safe and effective,and is worthy of promotion and application.

关 键 词：CHOP方案 美罗华 初治弥漫性大B细胞淋巴瘤 应用效果 

分 类 号：R733.1[医药卫生—肿瘤]